Home LiteratureArticle Details
PMID: 11531253 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma.

British journal of cancer ·Vol. 85 ·No. 5 ·2001-09-01 ·Pages 687-91

Francis-Thickpenny KM, Richardson DM, van Ee CC, Love DR, Winship IM, Baguley BC, Chenevix-Trench G, Shelling AN

Abstract

Epithelial ovarian carcinoma is often diagnosed at an advanced stage of disease and is the leading cause of death from gynaecological neoplasia. The genetic changes that occur during the development of this carcinoma are poorly understood. It has been proposed that IGFIIR, TGFbeta1 and TGFbetaRII act as a functional unit in the TGFbeta growth inhibitory pathway, and that somatic loss-of-function mutations in any one of these genes could lead to disruption of the pathway and subsequent loss of cell cycle control. We have examined these 3 genes in 25 epithelial ovarian carcinomas using single-stranded conformational polymorphism analysis and DNA sequence analysis. A total of 3 somatic missense mutations were found in the TGFbetaRII gene, but none in IGFRII or TGFbeta1. An association was found between TGFbetaRII mutations and histology, with 2 out of 3 clear cell carcinomas having TGFbetaRII mutations. This data supports other evidence from mutational analysis of the PTEN and beta-catenin genes that there are distinct developmental pathways responsible for the progression of different epithelial ovarian cancer histologic subtypes.

MeSH Terms
Carcinoma/genetics,pathology DNA Mutational Analysis Female Humans Mutation, Missense/genetics Neoplasm Proteins/genetics Neoplasm Staging Ovarian Neoplasms/genetics,pathology Polymorphism, Single-Stranded Conformational Protein Serine-Threonine Kinases Receptor, IGF Type 2/genetics Receptor, Transforming Growth Factor-beta Type II Receptors, Transforming Growth Factor beta/genetics Sequence Analysis, DNA Transforming Growth Factor beta/genetics
Chemicals
Neoplasm Proteins Receptor, IGF Type 2 Receptors, Transforming Growth Factor beta Transforming Growth Factor beta Protein Serine-Threonine Kinases Receptor, Transforming Growth Factor-beta Type II
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Francis-Thickpenny K M
Department of Obstetrics and Gynaecology, Research Centre in Reproductive Medicine, National Women's Hospital, Auckland, Australia.
Richardson D M
van Ee C C
Love D R
Winship I M
Baguley B C
Chenevix-Trench G
Shelling A N
References (32)
32 references, click to expand
  1. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines.
    J Biol Chem. 1999 Dec 3;274(49):35053-8 PMID: 10574984
  2. Molecular genetic analysis of TGF-beta1 in ovarian neoplasia.
    J Exp Clin Cancer Res. 1997 Mar;16(1):49-56 PMID: 9148861
  3. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.
    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2766-70 PMID: 2565038
  4. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  5. Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.
    Oncogene. 1992 Jun;7(6):1059-65 PMID: 1594239
  6. Structural framework for the protein kinase family.
    Annu Rev Cell Biol. 1992;8:429-62 PMID: 1335745
  7. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution.
    Nature. 1994 Feb 24;367(6465):704-11 PMID: 8107865
  8. Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells.
    J Biol Chem. 1994 May 6;269(18):13231-7 PMID: 8175753
  9. Molecular genetic analysis of TGF beta1 in breast cancer.
    J Exp Clin Cancer Res. 1997 Mar;16(1):57-63 PMID: 9148862
  10. Latent transforming growth factor-beta: structural features and mechanisms of activation.
    Kidney Int. 1997 May;51(5):1376-82 PMID: 9150447
  11. TGF-beta1 in colonic neoplasia: a genetic molecular and immunohistochemical study.
    J Exp Clin Cancer Res. 1997 Sep;16(3):281-8 PMID: 9387902
  12. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck.
    Carcinogenesis. 1997 Nov;18(11):2285-90 PMID: 9395234
  13. Cancer statistics, 1998.
    CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 PMID: 9449931
  14. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Cell Growth Differ. 1998 Feb;9(2):185-93 PMID: 9486855
  15. Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues.
    J Histochem Cytochem. 1998 Mar;46(3):379-88 PMID: 9487120
  16. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Cancer Res. 1998 May 15;58(10):2095-7 PMID: 9605750
  17. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma.
    Cancer Res. 1998 Oct 1;58(19):4227-32 PMID: 9766642
  18. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.
    Cell. 1998 Dec 11;95(6):779-91 PMID: 9865696
  19. Signal transduction. An anchor for activation.
    Nature. 1999 Jan 14;397(6715):109, 111 PMID: 9923670
  20. beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours.
    Int J Cancer. 1999 Aug 27;82(5):625-9 PMID: 10417756
  21. Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital.
    Carcinogenesis. 1994 Aug;15(8):1473-8 PMID: 8055622
  22. Homomeric interactions between type II transforming growth factor-beta receptors.
    J Biol Chem. 1994 Sep 9;269(36):22868-74 PMID: 7521335
  23. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.
    Gynecol Oncol. 1995 Feb;56(2):175-80 PMID: 7896181
  24. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors.
    Oncogene. 1995 May 4;10(9):1725-9 PMID: 7753549
  25. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells.
    Cancer Res. 1995 Sep 15;55(18):3982-7 PMID: 7664267
  26. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.
    Nat Genet. 1995 Dec;11(4):447-9 PMID: 7493029
  27. Negative regulation of cell growth by TGF beta.
    Biochim Biophys Acta. 1996 Mar 18;1242(3):185-99 PMID: 8603072
  28. Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast.
    Biochem Biophys Res Commun. 1996 Jun 25;223(3):561-4 PMID: 8687435
  29. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer.
    Genes Chromosomes Cancer. 1996 Apr;15(4):223-33 PMID: 8703848
  30. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
    Gynecol Oncol. 1996 Mar;60(3):412-7 PMID: 8774649
  31. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.
    Genes Chromosomes Cancer. 1997 Feb;18(2):75-83 PMID: 9115967
  32. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
    Cancer Res. 2000 Aug 15;60(16):4507-12 PMID: 10969799
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
2001-09-01
Pages
687-91
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2364123
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]